



November 7, 2025

**The General Manager**

Pakistan Stock Exchange Limited  
Stock Exchange Building,  
Stock Exchange Road,  
Karachi

**Subject: Corporate Briefing Session of Macter International Limited**

**Dear Sir,**

Further to our letter dated November 3, 2025 on the above subject, please find attached herewith presentation with respect to the Corporate Briefing Session (CBS) of Macter International Limited to be held on Monday, November 10, 2025 at 3:30 pm via Zoom video conferencing.

**Zoom link to join CBS:**

Join Zoom Meeting

<https://us02web.zoom.us/j/85802579171?pwd=Bney6dPmX7vd0St8DRTbjoz7Uopdcr.1>

Meeting ID: 858 0257 9171

Passcode: 648242

You may please inform the TRE Certificate Holders of the Exchange accordingly.

Yours truly,

For and on behalf of

Macter International Limited

Asif Javed

Company Secretary

Encl: as above



**WORKING TODAY**  
FOR A HEALTHIER TOMORROW

# ***Corporate Briefing Session***

*November 10, 2025*



# Disclaimer



## THIS PRESENTATION IS NOT AN OFFER OR SOLICITATION OF AN OFFER TO BUY OR SELL ANY SECURITIES OR ANY INVESTMENT

This presentation has been prepared by Macter International Limited (“Macter”) solely for information purposes. No representation or warranty express or implied is made thereto, and no reliance should be placed on, the fairness, accuracy, sufficiency, completeness or correctness of the information or any opinion contained herein, or any opinion rendered thereto. The information contained in this presentation should be considered in the context of the circumstances prevailing at the time and will not be updated to reflect any developments that may occur after the date of the presentation. Neither Macter nor any of its respective subsidiaries, affiliates, officials, advisors, associates, employees or any person working for, under or on behalf, shall have any responsibility and/or liability of any nature whatsoever (in contract or otherwise) for any loss whatsoever arising from any use of this presentation or its contents or otherwise arising in connection with this presentation.

This presentation does not constitute or form part of a prospectus, offering circular or offering memorandum or an offer, solicitation, invitation or recommendation to purchase or subscribe for any securities and no part of it shall form the basis of, or be relied upon in connection with, or act as any inducement to enter into any arrangement, agreement, contract, commitment or investment decision in relation to any securities. This presentation shall not at all be intended to provide any disclosure upon which an investment decision could be made. No money, securities or other consideration is being solicited, and, if sent in response to this presentation or the information contained herein, will not be accepted.

The presentation may contain statements that reflect Macter’s own beliefs and expectations about the future. These forward-looking statements are based on a number of assumptions about the future, which are beyond Macter’s control. Such forward-looking statements represent, in each case, only one of many possible scenarios and should not be viewed as the most likely or standard scenario. Such forward looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. Macter does not undertake any obligation to update any forward-looking statements to reflect events that occur or circumstances that arise after the date of this presentation and it does not make any representation, warranty (whether express or implied) or prediction that the results anticipated by such forward-looking statements will be achieved. In addition, past performance should not be taken as an indication or guarantee of future results.

Certain data in this presentation was obtained from various external data sources that Macter believes to its knowledge, information and belief to be reliable, but Macter has not verified such data with independent sources and there can be no assurance, representation or warranty as to the accuracy, sufficiency, correctness or completeness of the included data.

Accordingly, Macter makes no assurance, representation or warranty as to the accuracy, sufficiency, correctness or completeness of that data, and such data involves risks and uncertainties and is subject to change based on various factors.

You agree to keep the contents of this presentation strictly confidential. All or any part of this presentation may not be taken away, reproduced, copied, redistributed, retransmitted or disclosed in any manner or form and for any purpose whatsoever.

By attending this presentation, you are agreeing to be bound by the foregoing limitations.


# About Macter

*Macter International Limited is among the leading Pharmaceutical companies in Pakistan with a successful track record of 30 years. Our key manufacturing areas are MDI, DPI, cephalosporin, and biologicals including recently commissioned Pre-Filled Syringe (PFS) and Pre-Filled Pen (PFP) facilities.*



## Vision

*We see Macter as an integrated global healthcare company serving patients, healthcare professionals and customers with high quality and innovative products and services. We are committed to achieving our vision in an ethical and socially responsible manner.*



## Mission

*Macter exists to serve humanity by improving health and well-being; facilitating all associates to achieve their potential with dignity; and providing a means for an ethical and fair livelihood.*

## Values






# FINANCIAL HIGHLIGHTS

<i>Particulars</i>	<i>FY 2022-23</i>	<i>FY 2023-24</i>	<i>FY 2024-25</i>
<i>Sales</i>	<i>6,680</i>	<i>7,535</i>	<i>9,914</i>
<i>Gross Profit</i>	<i>2,785</i>	<i>3,182</i>	<i>4,458</i>
<i>Gross Margin</i>	<i>42%</i>	<i>42%</i>	<i>45%</i>
<i>Operating Profit</i>	<i>618</i>	<i>713</i>	<i>1,234</i>
<i>Profit After Tax</i>	<i>393</i>	<i>427</i>	<i>738</i>
<i>EPS</i>	<i>8.58</i>	<i>9.32</i>	<i>16.10</i>




Particulars	Q1 2025-26	Q1 2024-25	Growth
Sales	2,769	2,165	28%
Gross Profit	1,239	905	37%
Gross Margin	45%	42%	
Operating Profit	281	184	53%
Profit After Tax	156	93	68%
EPS	3.41	2.03	68%




Sales

Net turnover for the period ended September 30, 2025, was Rupees 2,769 million with a growth of 28%. All revenue categories (prescription, institution and export) registered double-digit growth. The profit level and profitability also demonstrated significant improvements during the period under review.



Gross Margin

Gross margin have experienced a significant increase of 3% primarily due to the better sales mix.



Operating Profit

Operating profit for the year is Rs. 281 Mn, representing a 53% growth over same period last year. This notable improvements is attributed to the higher sales, increase in gross profit margins and the implementation of efficiency enhancements and cost optimization measures.



# **CORPORATE HIGHLIGHTS**



# NEW MANUFACTURING FACILITY

## PRE-FILLED SYRINGE (PFS) & Pre-filled Pen (PFP) FACILITIES



Macter

*Macter has successfully commissioned and obtained the requisite licenses for its Pre-Filled Syringe (PFS) and Pre-Filled Pen (PFP) manufacturing facilities. Macter now has the capability to manufacture all three biotechnology dosage forms: Vials, Pre-Filled Syringes, and Pre-Filled Pens.*

*This is a significant milestone, marking a major advancement in the Company's biotechnology manufacturing capabilities and reinforcing the Company's aim to provide greater therapeutic benefits and convenience for patients in the local pharmaceutical and biotechnology sectors.*





# NEW LAUNCH


## SEMAGLUTIDE - PRE-FILLED SYRINGE (PFS) AND PRE-FILLED MULTI-DOSE PEN (PFP)



***Semaglutide - Glucagon-Like Peptide-1 (GLP-1) receptor agonist, a class of drugs widely used in the management of Type 2 Diabetes Mellitus and increasingly recognized for its role in weight management and metabolic health.***

***Macter has now become the only company in Pakistan offering Semaglutide in all three biotechnology dosage forms — Vials, Pre-Filled Syringes, and Pre-Filled Pens.***

***This milestone marks a significant advancement in Macter's Biotech portfolio and reinforces its leadership in bringing advanced, globally competitive therapies to patients in Pakistan.***





# ***Thank You Q & A Session***

